Patent: 6,970,741
✉ Email this page to a colleague
Summary for Patent: 6,970,741
Title: | Monitoring, preventing, and treating rejection of transplanted organs |
Abstract: | An implantable system control unit (SCU) includes means for measuring tissue impedance or other condition to determine allograft health, in order to predict or detect allograft rejection. The SCU also includes at least two electrodes coupled to means for delivering electrical stimulation to a patient within whom the device is implanted, and may also include a reservoir for holding one or more drugs and a driver means for delivering the drug(s) to the patient. In certain embodiments, the system is capable of open- and closed-loop operation. In closed-loop operation, at least one SCU includes a sensor, and the sensed condition is used to adjust stimulation parameters. Alternatively, this sensory \"SCU\" sounds an alarm, communicates an alarm to an external device, and/or is responsive to queries regarding sensed information, such as tissue impedance. |
Inventor(s): | Whitehurst; Todd K. (Frazier Park, CA), McGivern; James P. (Stevenson Ranch, CA), McClure; Kelly H. (Simi Valley, CA), Marnfeldt; Goran N. (Valencia, CA), Thacker; James R. (Eureka, MO) |
Assignee: | Advanced Bionics Corporation (Valencia, CA) |
Application Number: | 10/246,554 |
Patent Claims: | see list of patent claims |
Details for Patent 6,970,741
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2021-09-18 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2021-09-18 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2021-09-18 |
Biogen Inc. | ZINBRYTA | daclizumab | Injection | 761029 | 05/27/2016 | ⤷ Try a Trial | 2021-09-18 |
Biogen Inc. | ZINBRYTA | daclizumab | Injection | 761029 | 05/26/2017 | ⤷ Try a Trial | 2021-09-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |